Isturisa(Osilodrostat): New Hope For Cushing’s Syndrome Treatment
Cushing’s syndrome is a rare disease caused by the overproduction of cortisol from the adrenal glands, and patients often exhibit symptoms such as obesity, hypertension, and diabetes.
In recent years, important progress has been made in the treatment of this disease.
Approval And Application Of Isturisa
In January 2020, the European Medicines Agency (EMA) approved Isturisa (osilodrostat), developed by Recordati, for the treatment of endogenous Cushing’s syndrome in adults.
Osilodrostat controls or normalizes patients’ cortisol levels by inhibiting the enzyme 11-beta hydroxylase and reducing cortisol synthesis.
Clinical Studies And Efficacy
Isturisa demonstrated significant efficacy in the pivotal LINC-3 study. At the end of the 8-week randomized withdrawal period, a significantly higher percentage of patients in the Isturisa group maintained normal urinary free cortisol (mUFC) levels than in the placebo group (86.1% vs. 29.4%).
Data from the entire clinical program suggest that Isturisa normalizes cortisol levels in the majority of patients and improves multiple clinical characteristics and quality of life in this disease.
Global Rollout And Market Dynamics
In July 2019, Novartis sold three endocrine drugs, including Isturisa osilodrostat, to Italian pharmaceutical company Recordati for $390 million.
Since then, Recordati has aggressively pursued the registration and promotion of Isturisa globally.
In March 2020, Isturisa received U.S. Food and Drug Administration (FDA) approval for the treatment of patients with Cushing’s disease.
China Market Update
On September 28, 2024, osilodrostat was approved in China for the treatment of endogenous Cushing’s syndrome in adults. This approval brings a new treatment option for patients with Cushing’s syndrome in China and marks another important milestone in this area of therapy.
Conclusion
The global approval and application of Isturisa brings new hope to patients with Cushing’s syndrome. With more clinical experience and in-depth research, it is expected that this innovative therapy will benefit more patients and improve their quality of life.
However, HK DengYue’s efforts to increase the affordability of the medicine are critical to ensuring that more patients benefit from it.
We welcome you to reach out to us to buy Osilodrostat. DengYueMedicine is here to provide detailed medicine information, pricing, and support to ensure a smooth and reliable buying experience.
Feel free to contact us anytime to discuss your needs or ask any questions about the medicine.
Information from DengYueMed, China Drug Import and Export Wholesaler offers this information as a guide, not a substitute for professional medical advice. Consult your doctor before any treatment.
